The key questions that were discussed throughout this program were:
- Under the AIA’s inter partes review, who bears the burden of proof for demonstrating unpatentability?
- Under which sections of the Patent Act can challenges be brought to inter partes review?
- What are the timelines for filing petitions for inter partes review? What are the fees?
- What are the criteria for granting petitions for inter partes review?
- To what extent do Federal Rules of Evidence apply to inter partes review?
- How does the filing of Declaratory Judgment affect rights to pursue inter partes review?
- When is estoppel triggered in the context of inter partes review?
- How do discovery and Markman hearings in the context of inter partes review compare to traditional litigation?
- How do stays work with regard to inter partes review?
- How can failed patent challenges in inter partes review lead to a greater likelihood of the determination of willful infringement?
- To what extent do intervening rights exist for new claims incorporated into patents after inter partes review ?
Click here to learn more about this program.
Related Insights
21 October 2024
Events
Legal Overview of the BIOSECURE Act
Foley special counsel John Strom is speaking in the Association for Accessible Medicine’s GRx+Biosims 2024 conference in a panel titled “Legal Overview of the BIOSECURE Act” on October 21.
04 October 2024
Innovative Technology Insights
Decoding California’s Recent Flurry of AI Laws
Governor Newsom signed over 18 AI-related bills into law during September, impacting numerous industries.
17 October 2024
Events
Top Compliance Considerations when Commercializing in the U.S.
Kyle Faget and Nathan "Nate" Beaver, co-chair of Foley's Medical Device and Equipment Area of Focus within the firm's Health Care & Life Sciences Sector, invite you to join us for a webinar on the compliance considerations you need to know when you are commercializing your medical device products in the U.S.